Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, announced the successful completion of its latest funding round led by BioLife Solutions and BroadOak Capital Partners. The strategic investment positions the Seattle-based company to expand its portfolio of clinical-grade cell lines and advance commercialization of its innovative stem cell platforms.
Proprietary Technology Platform Expansion
The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating the company's proprietary FailSafe® and iACT™ engineering technologies alongside hypoimmune genetic edits. These modifications are integrated into Pluristyx's polyclonal, synthetic RNA reprogrammed iPSCs, which are specifically designed to support the development of next-generation genetically engineered, stem cell-derived therapies.
The funding will also support the commercialization of Pluristyx's recently launched PluriForm™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. This product offering represents a significant advancement in providing researchers with standardized tools for iPSC-based applications.
Strategic Partnership with Industry Leaders
BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy manufacturing, led the investment round alongside continued support from BroadOak Capital Partners, a specialist investor in the life science tools and services industry.
"We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment," said Benjamin Fryer, PhD, CEO of Pluristyx. "The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges."
Roderick de Greef, BioLife's Chairman and CEO, emphasized the strategic alignment between the companies: "We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency."
Addressing Critical iPSC Field Challenges
Daniel Friedman, Principal at BroadOak Capital Partners, highlighted the company's differentiated approach: "Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field."
The company's iPSC products serve multiple applications beyond therapeutic development, including innovative toxicology, safety, and efficacy assays designed to replace animal models. Pluristyx positions its products as the ideal universal raw material to produce living medicines targeting currently untreatable diseases.
Clinical and Commercial Applications
Pluristyx's iPSC lines are supported by an FDA registered drug master file and feature platform genetic engineering available "off-the-shelf" along with comprehensive support services. This approach is designed to accelerate the creation of novel diagnostics, screening and safety testing applications, and curative treatments.
The strategic investment enables Pluristyx to position itself as an industry leader offering high-quality stem cells for the rapidly expanding cell and gene therapy market. The company's integrated approach combining proprietary genetic modifications with standardized manufacturing processes addresses key scalability and safety challenges in the iPSC field.
